Vincent W. Vanek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent W. Vanek has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
American Society For Parenteral And Enteral Nutrition (A.S.P.E.N.) Board Of Directors
2 shared publicationsChristina J. Valentine
University of Cincinnati, Cincinnati, Ohio
2 shared publicationsMarty Kochevar
A.S.P.E.N., Silver Spring, Maryland
2 shared publicationsAlan Buchman
Northwestern University School of Medicine, Chicago, Illinois
1 shared publicationAlan Shenkin
Royal Liverpool University Hospital, Liverpool, England
1 shared publicationBruce Bistrian
Beth Israel Deaconess Medical Center, Boston, Massachusetts
1 shared publication
Latest Publications
- 16 October 2012
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 27 (6) , 718-737
Providing Nutrition Support in the Electronic Health Record Era
Background: Data are not available on the quantity or quality of nutrition support content in the currently available electronic health record (EHR) systems. Materials and Methods: A survey study of the American Society for Parenteral and Enteral Nutrition membership regarding the safety and efficacy of nutrition documentation and the ordering process for oral diets, oral supplements, tube feedings, and parenteral nutrition in currently used EHRs was conducted. The responses were converted to a rating of excellent, good, fair, poor, or unacceptable for each component. Results: The survey responders rated all 5 of the above EHR nutrition components only as fair. There were no differences between disciplines regarding how they rated these nutrition components. The responders who had been using their EHR for more than 10 years rated these components as fair to good, which was significantly better than those responders who have been using their EHR for less than a year, who rated these components from poor to fair. There was some variation in ratings given to the 7 different EHR vendors used by the responders, with 2 vendors having significantly poorer ratings than the other vendors. However, even the top‐rated vendors received ratings of only fair. Conclusions: This study should be a wake‐up call for EHR developers/vendors, healthcare systems, and clinicians that the nutrition and nutrition support content of the current EHRs needs significant improvements. Nutrition support clinicians need to be actively involved in optimizing this EHR content.
- 16 October 2012
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 27 (6) , 718-737
Providing Nutrition Support in the Electronic Health Record Era
Background: Data are not available on the quantity or quality of nutrition support content in the currently available electronic health record (EHR) systems. Materials and Methods: A survey study of the American Society for Parenteral and Enteral Nutrition membership regarding the safety and efficacy of nutrition documentation and the ordering process for oral diets, oral supplements, tube feedings, and parenteral nutrition in currently used EHRs was conducted. The responses were converted to a rating of excellent, good, fair, poor, or unacceptable for each component. Results: The survey responders rated all 5 of the above EHR nutrition components only as fair. There were no differences between disciplines regarding how they rated these nutrition components. The responders who had been using their EHR for more than 10 years rated these components as fair to good, which was significantly better than those responders who have been using their EHR for less than a year, who rated these components from poor to fair. There was some variation in ratings given to the 7 different EHR vendors used by the responders, with 2 vendors having significantly poorer ratings than the other vendors. However, even the top‐rated vendors received ratings of only fair. Conclusions: This study should be a wake‐up call for EHR developers/vendors, healthcare systems, and clinicians that the nutrition and nutrition support content of the current EHRs needs significant improvements. Nutrition support clinicians need to be actively involved in optimizing this EHR content.
- Open Access
- 22 June 2012
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 27 (4) , 440-491
A.S.P.E.N. Position Paper
The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet the requirements for most patients who receive parenteral nutrition (PN). However, a separate parenteral vitamin D preparation (cholecalciferol or ergocalciferol) should be made available for treatment of patients with vitamin D deficiency unresponsive to oral vitamin D supplementation. Carnitine is commercially available and should be routinely added to neonatal PN formulations. Choline should also be routinely added to adult and pediatric PN formulations; however, a commercially available parenteral product needs to be developed. The parenteral multi–trace element (TE) preparations that are commercially available in the U.S. require significant modifications. Single‐entity trace element products can be used to meet individual patient needs when the multiple‐element products are inappropriate (see Summary/A.S.P.E.N. Recommendations section for details of these proposed modifications).
- 22 June 2012
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 27 (4) , 440-491
Open AccessA.S.P.E.N. Position Paper
The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet the requirements for most patients who receive parenteral nutrition (PN). However, a separate parenteral vitamin D preparation (cholecalciferol or ergocalciferol) should be made available for treatment of patients with vitamin D deficiency unresponsive to oral vitamin D supplementation. Carnitine is commercially available and should be routinely added to neonatal PN formulations. Choline should also be routinely added to adult and pediatric PN formulations; however, a commercially available parenteral product needs to be developed. The parenteral multi–trace element (TE) preparations that are commercially available in the U.S. require significant modifications. Single‐entity trace element products can be used to meet individual patient needs when the multiple‐element products are inappropriate (see Summary/A.S.P.E.N. Recommendations section for details of these proposed modifications).
- 29 February 2012
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 27 (2) , 150-192
A.S.P.E.N. Position Paper
The currently available, standard soybean oil (SO)–based intravenous fat emulsions (IVFEs) meet the needs of most parenteral nutrition (PN) patients. There are alternative oil‐based fat emulsions, such as medium‐chain triglycerides (MCTs), olive oils (OOs), and fish oils (FOs), that, based on extensive usage in Europe, have an equivalent safety profile to SO. These alternative IVFEs are metabolized via different pathways, which may lead to less proinflammatory effects and less immune suppression. These alternative oil‐based IVFEs are not currently available in the United States. Many patients who require IVFEs are already in a compromised state. Such patients could potentially have better clinical outcomes when receiving one of the alternative IVFEs to diminish the intake of the potentially proinflammatory ω‐6 fatty acid—linoleic acid—which comprises more than 50% of the fatty acid profile in SO. Further research is needed on these alternative oil‐based IVFEs to identify which IVFE oils or which combination of oils may be most clinically useful for specific patient populations.
- 29 February 2012
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 27 (2) , 150-192
A.S.P.E.N. Position Paper
The currently available, standard soybean oil (SO)–based intravenous fat emulsions (IVFEs) meet the needs of most parenteral nutrition (PN) patients. There are alternative oil‐based fat emulsions, such as medium‐chain triglycerides (MCTs), olive oils (OOs), and fish oils (FOs), that, based on extensive usage in Europe, have an equivalent safety profile to SO. These alternative IVFEs are metabolized via different pathways, which may lead to less proinflammatory effects and less immune suppression. These alternative oil‐based IVFEs are not currently available in the United States. Many patients who require IVFEs are already in a compromised state. Such patients could potentially have better clinical outcomes when receiving one of the alternative IVFEs to diminish the intake of the potentially proinflammatory ω‐6 fatty acid—linoleic acid—which comprises more than 50% of the fatty acid profile in SO. Further research is needed on these alternative oil‐based IVFEs to identify which IVFE oils or which combination of oils may be most clinically useful for specific patient populations.
- 1 September 2008
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 32 (5) , 535-562
A.S.P.E.N.—Past, Present, and Future
- 1 September 2008
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 32 (5) , 535-562
A.S.P.E.N.—Past, Present, and Future
- 1 February 2007
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 22 (1) , 22-28
Efficacy of Gastric Bypass in the Treatment of Obesity‐Related Comorbidities
Background: Obesity is associated with multiple comorbidities, including hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus, obstructive sleep apnea, osteoarthritis, back/extremity pain, gastroesophageal reflux disease (GERD), asthma, and depression. Surgical weight loss can markedly improve if not resolve many of these comorbidities. Methods: This was a retrospective study of 400 consecutive gastric bypass patients, analyzing postoperative resolution or improvement of obesity‐related comorbidities. Results: Mean follow‐up period for these patients was 12.8 months, with a range of 0.3–30.6 months. Comorbidities were present in 21%–65% of the patients. Hypertension, hyperlipidemia, diabetes mellitus, obstructive sleep apnea, GERD, and asthma either resolved or improved in 80%–100% of the patients. Arthritis, back or extremity pain, and depression also improved but to a lesser extent, in 52%–73% of patients. Our patients' quality of life greatly improved even at 6 weeks postoperatively in 35% of the patients, and this increased to> 80% after 18 months. Conclusions: Gastric bypass surgery for the treatment of morbidly obese patients has a profound positive impact on obesity‐related comorbidities. Also, patients' quality of life is dramatically improved in the majority of patients when compared with their preoperative status.
- 1 February 2007
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 22 (1) , 22-28
Efficacy of Gastric Bypass in the Treatment of Obesity‐Related Comorbidities
Background: Obesity is associated with multiple comorbidities, including hypertension, hypercholesterolemia, hypertriglyceridemia, diabetes mellitus, obstructive sleep apnea, osteoarthritis, back/extremity pain, gastroesophageal reflux disease (GERD), asthma, and depression. Surgical weight loss can markedly improve if not resolve many of these comorbidities. Methods: This was a retrospective study of 400 consecutive gastric bypass patients, analyzing postoperative resolution or improvement of obesity‐related comorbidities. Results: Mean follow‐up period for these patients was 12.8 months, with a range of 0.3–30.6 months. Comorbidities were present in 21%–65% of the patients. Hypertension, hyperlipidemia, diabetes mellitus, obstructive sleep apnea, GERD, and asthma either resolved or improved in 80%–100% of the patients. Arthritis, back or extremity pain, and depression also improved but to a lesser extent, in 52%–73% of patients. Our patients' quality of life greatly improved even at 6 weeks postoperatively in 35% of the patients, and this increased to> 80% after 18 months. Conclusions: Gastric bypass surgery for the treatment of morbidly obese patients has a profound positive impact on obesity‐related comorbidities. Also, patients' quality of life is dramatically improved in the majority of patients when compared with their preoperative status.
- 1 January 2006
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 2 (1) , 17-22
Retrospective review of the preoperative biliary and gastrointestinal evaluation for gastric bypass surgery
- 1 January 2006
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 2 (1) , 17-22
Retrospective review of the preoperative biliary and gastrointestinal evaluation for gastric bypass surgery
- 1 July 2005
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 1 (4) , 424-429
State laws on insurance coverage for bariatric surgery: help or a hindrance?
- 1 July 2005
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 1 (4) , 424-429
State laws on insurance coverage for bariatric surgery: help or a hindrance?
- 1 June 2003
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 18 (3) , 201-220
Ins and Outs of Enteral Access. Part 3: Long‐Term Access—Jejunostomy
Feeding jejunostomy tubes can be useful in patients with gastroesophageal reflux or a nonfunctioning stomach and can be short‐term, long‐term, or permanent. These tubes can be inserted surgically, endoscopically, radiologically, or laparoscopically. Each of these techniques is described, and their mortality, morbidity, advantages, and disadvantages are compared.
- 1 June 2003
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 18 (3) , 201-220
Ins and Outs of Enteral Access. Part 3: Long‐Term Access—Jejunostomy
Feeding jejunostomy tubes can be useful in patients with gastroesophageal reflux or a nonfunctioning stomach and can be short‐term, long‐term, or permanent. These tubes can be inserted surgically, endoscopically, radiologically, or laparoscopically. Each of these techniques is described, and their mortality, morbidity, advantages, and disadvantages are compared.
- 1 February 2003
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 18 (1) , 50-74
Ins and Outs of Enteral Access: Part 2—Long Term Access—Esophagostomy and Gastrostomy
Access techniques for long‐term enteral nutrition (over 4 to 6 weeks) includes cervical esophagostomy and pharyngostomy, gastrostomy, and jejunostomy. Cervical esophagostomy and pharyngostomy are rarely used since the advent of better long‐term enteral access techniques that are easier to care for and have fewer complications; they are briefly reviewed only for historical completeness and to condemn their use. The different techniques of gastrostomy tube insertion and their indications, contraindications, advantages, and disadvantages are discussed. Part III (to be published in a later issue) of this series will review feeding jejunostomy.
- 1 February 2003
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 18 (1) , 50-74
Ins and Outs of Enteral Access: Part 2—Long Term Access—Esophagostomy and Gastrostomy
Access techniques for long‐term enteral nutrition (over 4 to 6 weeks) includes cervical esophagostomy and pharyngostomy, gastrostomy, and jejunostomy. Cervical esophagostomy and pharyngostomy are rarely used since the advent of better long‐term enteral access techniques that are easier to care for and have fewer complications; they are briefly reviewed only for historical completeness and to condemn their use. The different techniques of gastrostomy tube insertion and their indications, contraindications, advantages, and disadvantages are discussed. Part III (to be published in a later issue) of this series will review feeding jejunostomy.
- 1 October 2002
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 17 (5) , 275-283
Ins and Outs of Enteral Access. Part 1: Short‐Term Enteral Access
Proper selection of the type of enteral access in a given clinical situation is important to maximize the benefit to the patient and minimize the discomfort to the patient, the morbidity and mortality, and the cost. This decision is based on whether or not the patient needs short‐term (<4–6 weeks) or long‐term enteral nutrition support. This article focuses on short‐term access including nasogastric (NG) and nasoenteric (NE) tubes and reviews each of these enteral access tubes along with their indications, contraindications, advantages, and disadvantages.
- 1 October 2002
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 17 (5) , 275-283
Ins and Outs of Enteral Access. Part 1: Short‐Term Enteral Access
Proper selection of the type of enteral access in a given clinical situation is important to maximize the benefit to the patient and minimize the discomfort to the patient, the morbidity and mortality, and the cost. This decision is based on whether or not the patient needs short‐term (<4–6 weeks) or long‐term enteral nutrition support. This article focuses on short‐term access including nasogastric (NG) and nasoenteric (NE) tubes and reviews each of these enteral access tubes along with their indications, contraindications, advantages, and disadvantages.